

Darunavir expanded access

Created 11 Jun 2010 - 5:28pm

The approval follows the results of the TITAN study that showed Prezista has fewer side effects than other treatments in the same class. These include heart problems, yellowing of the skin, interactions with ulcer and reflux medication and the more serious and debilitating cases of diarrhoea.

'The HIV community is very pleased that it is now more broadly available,' said Jo Watson, Executive Director of NAPWA.

Prezista has also demonstrated [effectiveness](#) [1](Of a drug or treatment). The maximum ability of a drug or treatment to produce a result regardless of dosage. A drug passes efficacy trials if it is effective at the dose tested and against the illness for which it is prescribed. In the standard procedure, Phase II clinical trials gauge efficacy, and Phase III trials confirm it. In other trials looking at once daily dosing, and monotherapy (taking one HIV drug at a time).

Initial results of another trial have shown that if people have been taking a combination containing the drug and have had an undetectable [viral load](#) [2]A measurement of the quantity of HIV RNA in the blood. Viral load blood test results are expressed as the number of copies (of HIV) per milliliter of blood plasma. For six months, they may be able to take Prezista alone and still maintain an undetectable viral load.

The trials continue.

- [Treating HIV](#)
- [Accessing HIV care and treatment](#)
- [darunavir](#)
- [darunavir](#)
- [news](#)
- [Pharmaceutical Benefits Scheme](#)

Links:

[1] <http://www.napwa.org.au/glossary/term/486>

[2] <http://www.napwa.org.au/glossary/term/416>